Liver Cancer (Hepatocellular Carcinoma) clinical trials in Texas
72 active Liver Cancer (Hepatocellular Carcinoma) trials with a site in Texas. Describe your situation to see which ones look like a fit.
- Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
- A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Ligufalimab and Cadonilimab in Advanced Liver Cancers
- Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
- Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
- Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- A Study of ZW251 in Participants With Advanced Solid Tumors
- Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- FOG-001 in Locally Advanced or Metastatic Solid Tumors
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
- DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
- A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
- Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- IDOV-Immune for Advanced Solid Tumors
- A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- A Study of DM005 in Patients With Advanced Solid Tumors
- A Beta-only IL-2 ImmunoTherapY Study
- Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.